TheProfitWatch

CGON - CG Oncology, Inc. Common stock

Day 1m 10m 60m PreMarket Market AfterHours Gap
40.95 0.98 (2.39%) -0.06 (-0.14%) -0.07 (-0.17%) -0.24 (-0.57%) 0.0 (0.0%) 1.67 (4.15%) 0.0 (0.0%) 0.45 (1.11%)

CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.

Category: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Market Period: Market

Earnings & Ratios

Basic EPS:
-0.54
Diluted EPS:
-0.54
Basic P/E:
-77.6481
Diluted P/E:
-77.6481
RSI(14) 1m:
30.0
VWAP:
41.97
RVol:

Events

Period Kind Movement Occurred At

Related News